Patients With Advanced Breast Cancer Denied Routine Access To Breakthrough Treatment,

[News]

Novartis today expressed great disappointment that the National Institute for Health and Care Excellence (NICE) has issued a final decision not to recommend its innovative advanced breast cancer treatment, Afinitor® (everolimus), to be available to patients on the NHS...

More... (http://www.medicalnewstoday.com/releases/262966.php)